F2G

First in class anti-fungal agents

F2G has identified a novel fungal target essential for DNA synthesis, and so fungal growth and survival. The company has identified novel inhibitors of this enzyme with the lead candidate F901318 in Phase II clinical trials. F901318 has the potential to be the first new class of anti-fungal agent for over 30 years.

CEO  Francesco Maria Lavino

f2g.com

Advent Contact  Kaasim Mahmood

Private Companies
19 December 2022 in F2G, Press Release, Private Companies

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Press Release.   Application submitted under priority review with PDUFA target action date set for June 17, 2023 NDA submission is based on positive data from ongoing Phase 2b open-label…
Read More
4 August 2022 in F2G, Press Release, Private Companies

F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim

Press Release.   MANCHESTER, UK, 4 August 2022 – F2G Ltd, a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening rare fungal infections…
Read More
16 May 2022 in F2G, Press Release, Private Companies

Shionogi & Co., Ltd. and F2G Ltd., Enter Strategic Collaboration to Develop and Commercialize the New Antifungal Agent Olorofim in Europe and Asia

Press Release.   Shionogi to conduct clinical trials, subsequent registration and commercialization of olorofim for invasive aspergillosis IA in Europe and Asia F2G to receive u pfront payment of $100…
Read More
12 April 2021 in F2G, Press Release, Private Companies

Francesco Maria Lavino appointed Chief Executive Officer of F2G Ltd

Press Release.   Brings substantial pharmaceutical expertise to lead the development and commercialization of olorofim in the USA Ian Nicholson stepping down to pursue non-executive roles MANCHESTER, UK / VIENNA,…
Read More
22 October 2020 in F2G, Press Release, Private Companies

F2G Receives Second US FDA Breakthrough Therapy Designation for Olorofim

Press Release.   In Phase 2b development for the treatment of life-threatening fungal infections First antifungal agent to receive Breakthrough Therapy Designation New second Breakthrough Therapy Designation for CNS Valley…
Read More
12 August 2020 in F2G, Press Release, Private Companies

F2G Closes US$60.8 Million Financing to fund late stage development of novel mechanism antifungal agent

Press Release.   Financing round led by Cowen Healthcare Investments with strong support from existing investors Novo Holdings, Morningside Ventures, Brace Pharma Capital and Advent Life Sciences MANCHESTER, UK /…
Read More
11 November 2019 in F2G, Press Release, Private Companies

F2G Receives US FDA Breakthrough Therapy Designation for Olorofim

Press Release.   MANCHESTER, UK / VIENNA, Austria – November 11, 2019 – F2G Ltd, a UK- and Austria-based biotech company developing novel therapies for life-threatening systemic fungal infections, announced…
Read More
8 April 2019 in F2G, Press Release, Private Companies

F2G appoints Dr Patrick Vink as Chairman

Press Release.   Brings successful track record of building and growing global businesses MANCHESTER, UK & VIENNA, AUSTRIA – 8 April 2019 – F2G Ltd, the European biotech company developing…
Read More
27 September 2017 in F2G, Press Release, Private Companies

KaNDy Therapeutics launched to advance a breakthrough treatment in Women’s Health

Press Release.   KaNDy Therapeutics launched to advance a breakthrough treatment in Women's Health Press Release: KaNDy Therapeutics launched to advance a breakthrough treatment in Women's Health First-in-class once daily…
Read More
20 June 2016 in F2G, Press Release, Private Companies

F2G Ltd Announces $60 Million Financing to Progress Development of Novel Antifungal Agents

Press Release.   Funding to Take Lead Compound Through to Product Approval and Development of Pipeline Assets MANCHESTER, UK – 20 June 2016 – F2G Ltd, the UK-based antifungal drug…
Read More
28 January 2014 in F2G, Press Release, Private Companies

First Clinical Trial for NeRRe Therapeutics

Press Release.   First Clinical Trial for NeRRe Therapeutics Press Release: Start of Phase II study of neurokinin-1 receptor antagonist orvepitant for intense pruritus induced by epidermal growth factor receptor…
Read More
11 March 2013 in F2G, Press Release, Private Companies

F2G Ltd. Appoints Ian Nicholson as Chief Executive Officer Manchester

Press Release.   March 11th 2013 F2G Ltd. Appoints Ian Nicholson as Chief Executive Officer Manchester F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment…
Read More
5 September 2012 in F2G, Press Release, Private Companies

F2G Ltd Completes $30 Million Financing Round to Fund Pre-clinical and Clinical Development of Novel Anti-fungal Compounds

Press Release.   Manchester, UK, Sept 5th 2012 - F2G Limited, an antifungal drug discovery and development company, today announced the completion of a $30 million equity financing round in…
Read More